Why did PHASQ stock drop so steeply today?

The steep drop reflects extremely low liquidity, residual effects of past Chapter 11 proceedings, negative EPS of **-2.14**, and absence of near-term positive catalysts. Thin volume (today **2,500**) magnified price moves on PNK.

What is Meyka AI’s grade for PHASQ and what does it mean?

Meyka AI rates PHASQ **62.87/100** with a **B** and a **HOLD** suggestion; the grade factors S&P 500 and sector comparison, financial growth, key metrics, forecasts, and analyst consensus. Grades are informational and not investment advice.

What are the main financial risks for PhaseBio (PHASQ)?

Main risks include negative operating cash flow per share (**-1.61**), negative book value per share (**-3.16**), potential dilution, and delisting risk on PNK. Those factors heighten downside risk for PHASQ stock.

Does Meyka AI offer a price forecast for PHASQ stock?

Yes, Meyka AI's forecast model projects **$0.00200** in 12 months versus the current **$0.000001**, implying a model-based upside of **199,900.00%**, but forecasts are model-based projections and not guarantees.

US Stocks

PHASQ stock slumps 99% on PNK 19 Mar 2026: clear risk for investors

ByHuzaifa Zahoor March 19, 2026March 19, 2026

PHASQ stock fell 99.00% to $0.000001 on the PNK exchange during market hours on 19 Mar 2026, making it one of today’s top losers. Trading volume was 2,500 shares versus a 50-day average of 22,310, signaling very thin liquidity. This sudden plunge follows persistent post-reorganization weakness, a negative earnings profile (EPS -2.14), and limited visible catalysts in the near term.